MacuCLEAR’s Co-founder, Senior Advisor, and inventor, has developed a pipeline of compounds for treating various diseases of the eye. The lead compound MC-1101, is a 505 b 2, repurposed compound, formerly used as an anti-hypertensive drug. Its vasodilation, anti-inflammatory, and antioxidation combined properties proved effective in modulating choroidal blood flow in human clinical trials. MacuCLEAR’s pipeline includes a total of at least 12 separate compounds of various types that are intended to be second generation dry AMD compounds, and in some cases treat other retinal diseases such as diabetic retinopathy and diabetic macula edema. Ten of these proprietary compounds are new chemical entities.